• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life sciences >Effect of recombinant human SDF-1a on re-endothelialization after sirolimus-eluting stent implantation in rabbit aorta abdominalis.
【24h】

Effect of recombinant human SDF-1a on re-endothelialization after sirolimus-eluting stent implantation in rabbit aorta abdominalis.

机译：重组人SDF-1A对兔主动脉灌注型肠道植入术后重新内皮化的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIMS: Although the use of drug-eluting stents (DES) has been shown to limit neointimal hyperplasia in clinical coronary artery disease treatment, currently available DES may adversely affect re-endothelialization (RE) and thus increase fateful stent thrombosis. As stromal cell derived factor 1a (SDF-1a) plays an essential role in the regulation of endothelial progenitor cells (EPCs) mobilization, homing, and differentiation in response to vascular injury, we assumed that SDF-1a may enhance EPCs adhesion and attenuate delayed RE associated with DES. MAIN METHODS: Biologically active recombinant human SDF-1a (rhSDF-1a) was first produced using an Escherichia coli expression system. Twenty-four male rabbits were then underwent sirolimus-eluting stents implantation in aorta abdominalis. After operation, they were randomly divided into two groups and subcutaneously injected daily with 50 mug/kg rhSDF-1a or the same volume of saline for 7 days. KEY FINDINGS: With the application of scanning electron microscopy (SEM) and histological analysis, we found that rhSDF-1a significantly promoted RE on days 7, 14, 28 and inhibited neointimal hyperplasia on day 28 after stent implantation. SIGNIFICANCE: Our results revealed a potential role of rhSDF-1a in facilitating RE and inhibiting neointimal proliferation after DES implantation, leading to a conclusion that this protein may be a potential candidate agent for the treatment of in-stent restenosis and stent thrombosis.
机译：目的：虽然已经显示使用药物洗脱支架（DES）来限制临床冠状动脉疾病治疗中的内膜增生，但目前可用的DES可能会对重新内皮化（RE）产生不利影响，从而增加命运支架血栓形成。作为基质细胞衍生因子1A（SDF-1A）在调节内皮祖细胞（EPC）的调节中起重要作用，响应于血管损伤，我们认为SDF-1A可以增强EPC粘附和衰减延迟与des相关联。主要方法：首先使用大肠杆菌COLI表达系统制备生物活性重组人SDF-1A（RHSDF-1A）。然后在主动脉灌肠中植入二十四只雄性兔子在主动脉植入血管植入。操作后，将它们随机分为两组，每日皮下注射50麦克/ kg rHSDF-1a或相同的盐水7天。主要发现：随着扫描电子显微镜（SEM）和组织学分析的应用，我们发现RHSDF-1A在第7天，第14,28天的RE促进RE，并在支架植入后第28天抑制新内膜增生。重要意义：我们的研究结果揭示了RHSDF-1A在植入后促进RE和抑制内膜增殖的潜在作用，从而得出结论，即该蛋白质可能是治疗支架内再狭窄和支架血栓形成的潜在候选剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号